title: Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods.
abstract: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family. The accumulated evidence on the tumor-progressing roles of HB-EGF has suggested that HB-EGF-targeted cancer therapy is expected to be promising. However, the generation of neutralizing anti-HB-EGF monoclonal antibodies (mAbs) has proved difficult. To overcome this difficulty, we performed a hybridoma approach using mice from different genetic backgrounds, as well as different types of HB-EGF immunogens. To increase the number of hybridoma clones to screen, we used an electrofusion system to generate hybridomas and a fluorometric microvolume assay technology to screen anti-HB-EGF mAbs. We succeeded in obtaining neutralizing anti-HB-EGF mAbs, primarily from BALB/c and CD1 mice, and these were classified into 7 epitope bins based on their competitive binding to the soluble form of HB-EGF (sHB-EGF). The mAbs showed several epitope bin-dependent characteristics, including neutralizing and binding activity to human sHB-EGF, cross-reactivity to mouse/rat sHB-EGF and binding activity to the precursor form of HB-EGF. The neutralizing activity was also validated in colony formation assays. Interestingly, we found that the populations of mAb bins and the production rates of the neutralizing mAbs were strikingly different by mouse strain and by immunogen type. We succeeded in generating a variety of neutralizing anti-HB-EGF mAbs, including potent sHB-EGF neutralizers that may have potential as therapeutic agents for treating HB-EGF-dependent cancers. Our results also suggest that immunization approaches using different mouse strains and immunogen types affect the biological activity of individual neutralizing antibodies.
authors.affiliation: Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, Fujisawa, Kanagawa, Japan.
authors.forename: Isamu
authors.initials: I
authors.lastname: Tsuji
authors.forename: Shuji
authors.initials: S
authors.lastname: Sato
authors.forename: Kentaro
authors.initials: K
authors.lastname: Otake
authors.forename: Takahiro
authors.initials: T
authors.lastname: Watanabe
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kamada
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Kurokawa
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000276:immunology*; D004333:Drug Administration Routes; D004815:Epidermal Growth Factor / Q000276:immunology*; D006493:Heparin / Q000276:immunology*; D006801:Humans; D006825:Hybridomas; D007114:Immunization; D051379:Mice; D008815:Mice, Inbred Strains; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D004815:Epidermal Growth Factor; D006493:Heparin